The Gut Microbiome impacts anti-tumor response to cancer therapy

On Friday, January 25, 2019, the CRCHUM Conferences will host Laurence Zitvogel, professor in the department of immunology biology of the University of Paris 11.

Abstract

The fine line between human health and disease can be driven by the interplay between host and microbial factors. This “metagenome” regulates cancer initiation, progression, and response to therapies. Besides the capacity of distinct microbial species to modulate the pharmacodynamics of chemotherapeutic drugs, symbiosis between epithelial barriers and their microbial ecosystems has a major impact on the local and distant immune system, markedly influencing clinical outcome in cancer patients. Efficacy of cancer immunotherapy with immune checkpoint antibodies can be diminished with administration of antibiotics, and superior efficacy is observed with the presence of specific gut microbes. Future strategies of precision medicine will likely rely on novel diagnostic and therapeutic tools with which to identify and correct defects in the microbiome that compromise therapeutic efficacy.

Guest of Dr Bertrand Routy. Axe Cancer.

This conference will be presented in English.

Friday, January 25, at noon
Auditorium of the CRCHUM , R05.210 and R05.220
900 Saint-Denis Street, 5th floor 
Montreal (Quebec), H2X 0A9

Laurence Zitvogel, M.D. Ph.D.
Director of the Center for Clinical investigations in biotherapies Curie / IGR
Professor in the department of immunology biology of the University of Paris 11
Director of the INSERM Unit

About CRCHUM Conferences

The CRCHUM Conferences are free weekly meetings featuring renowned scientific speakers from various disciplines. These conferences are accredited by the Royal College of Physicians and Surgeons of Canada as continuing professional development activities. 
 

About our scientific activities

> Schedule of the CRCHUM Conferences and the scientific activities at the CRCHUM (in French)